Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. II. Pharmacological profile

Journal of Pharmacology and Experimental Therapeutics

Volumn 277, Issue 1, 1996, Pages 265-277

  Caille, Dominique ^a   Bergis, Olivier Emmanuel ^a   Fankhauser, Christine ^a   Gardes, Arlette ^a   Adam, Roselyne ^a   Charieras, Thierry ^a   Grosset, Alain ^a   Rovei, Vincenzo ^a   Jarreau, Francois Xavier ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYTRYPTOPHAN; BEFLOXATONE; BICUCULLINE; BROFAROMINE; CLORGYLINE; FLUOXETINE; MOCLOBEMIDE; MONOAMINE OXIDASE A INHIBITOR; NIALAMIDE; PHENELZINE; PHENETHYLAMINE; RESERPINE; TRANYLCYPROMINE; TYRAMINE;

AKINESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG POTENCY; DRUG SELECTIVITY; HYPOTHERMIA; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PTOSIS; RAT; STEREOTYPY; TRANQUILIZING ACTIVITY; TREMOR;

ANIMALS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; CHOLINERGIC ANTAGONISTS; MALE; MICE; MONOAMINE OXIDASE INHIBITORS; MOTOR ACTIVITY; OXAZOLES; RATS; RATS, SPRAGUE-DAWLEY; SLEEP, REM; SWIMMING; TYRAMINE;

EID: 0030439768     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. AMREIN, R., ALLEN, S. R., VRANESIC, D. AND STABL, M.: Antidepressant drug therapy: Associated risks. J. Neural Transm. 26: (Suppl.) 73-86, 1988.
2. AMREIN, R., GÜNTERT, T. W., DINGEMANSE, J., LORSCHEID, T., STABL, M. AND SCHMID-BURGK, W.: Interactions of moclobemide with concomitantly administered medication: Evidence from pharmacological and clinical studies. Psychopharmacology 106: 24-31, 1992.
3. BIECK, P. R. AND ANTONIN, K. H.: Tyramine potentiation during treatment with MAO inhibitors: Brofaromine and moclobemide vs. irreversible inhibitors. J. Neural Transm 28: (Suppl.) 21-31, 1989.
4. BLACKWELL, B.: Hypertensive crises due to mono amine oxidase inhibitors. Lancet 2: 849-851, 1963
5. PRAESTRUP, C., ANDERSEN, H. AND RANDRUP, A.: The monoamine oxidase B inhibitor deprenyl potentiates phenylethylamine behaviour in rats without inhibition of catecholamine metabolite formation. Eur. J. Pharmacol. 34: 181-187, 1975.
6. BURKARD, W. P., BONETTI, E. P., DA PRADA, M., MARTIN, J. R., POLC, P., SCHAFFNER, R., SCHERSCHLICHT, R., HEFTI, F., MULLER, R. K. M., WYSS, P. C. AND HAEFELY, W.: Pharmacological profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. J. Pharmacol. Exp. Ther. 248: 391-399, 1989.
7. CAILLE, D., ADAM, R., BERGIS, O. E., FANKHAUSER, C., GARDES, A. AND MARTIN, P.: Pharmacological profile of befloxatone, a new reversible MAO-A inhibitor. Proceedings XVIII CINP Nice. Clin. Neuropharmacol. 15: 423B, 1992.
8. CHOUVET, G., ODET, P., VALATX, J. L. AND PUJOL, J. F.: An automatic sleep classifier for laboratory rodents. Waking and sleeping 4: 9-31, 1980.
9. COLE, J. O.: Therapeutic efficacy of antidepressant: J. Am. Med. Assoc. 190: 448-455, 1964.
10. CURET, O., DAMOISEAU, G. AND AUBIN, N.: Biochemical profile of befloxatone, a new reversible MAO-A inhibitor. Proceedings XVIII CINP Nice. Clin. Neuropharmacol. 15: 424B, 1992.
11. CURET, O., DAMOISEAU, G., AUBIN, N., SONTAG, N., ROVEI, V. AND JARREAU, F. X.: Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. I. Biochemical profile. J. Pharmacol. Exp. Ther. 277: 253-264, 1996.
12. CURET, O., DAMOISEAU, G., LABAUNE, J. P., ROVEI, V. AND JAEREAU, F. X.: Effects of befloxatone, a new potent reversible MAO-A inhibitor, on cortex and striatum monoamines in freely moving rats. J. Neural Transm. 41: (Suppl.) 349-355, 1994.
13. DAJAS, F., VRANESIC, D., MARTINEZ, S., ALLEN, S. AND STABL, M.: Changes in sensitivity to tyramine after moclobemide treatment in depressed patients. In Moclobemide, a New MAO Inhibitor for the Treatment of Depression, 15th Latin-American Congress of Psychiatry. Satellite Symposium, November 26th, 1987, Buenos Aires, Argentina, ed. by J. Ward and F. Bringolf, pp. 16-19, Roche, Basle, 1988.
14. DA PRADA, M., KETTLER, R., BURKARD, W. P. AND HAEFELY, W. E.: Moclobemide, an antidepressant with short-lasting MAO-A inhibition: Brain catecholamines and tyramine pressor effects in rats. In Monoamine Oxidase and Disease. Prospects for Therapy with Reversible Inhibitors, ed. by K. F. Tipton, P. Dostert and M Strolen-Benedetti, pp. 137-154, Academic Press, London, 1984.
15. DA PRADA, M., KETTLER, R., KELLER, H. H., BURKARD, W. P., MUGGLI-MANIGLIO, D. AND HAEFELY W. E.: Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. J. Pharmacol. Exp. Ther. 248: 400-414, 1989.
16. DA PRADA, M., ZURCHER, G., WUTRICH, I. AND HAEFELY, W. E.: On tyramine, food, beverages and the reversible MAO inhibitor moclobemide. J. Neural Transm. 26: 31-56, 1988.
17. EGO, D., PARISY, D. AND PATTANO, N.: Pharmacokinetics of befloxatone, a new reversible inhibitor of MAO-A in rat. Proceedings XVIII CINP Nice, Clin. Neuropharmacol. 15: 422B, 1992.
18. EVERETT, G. M.: The dopa response potentiation test and its use in screening for antidepressant drugs. In Proceedings of the First International Symposium on Antidepressant Drugs, ed. by S. Garattini and M. N. G. Dukes, pp. 164-167, Excerpta Medica Foundation, Milan, 1967.
19. EVERETT, G. M. AND WIEGAND, R. G.: Central amines and behavioral states, a critique and new data. In Proceedings of the First International Pharmacological Meeting, Stockholm, August, 1961. ed. by B. Uvnaes, pp. 85-92, Pergamon Press, Oxford, 1962.
20. FANKHAUSER, C., CHARIERAS, T., CAILLE, D. AND ROVEI, V.: Interaction of MAO inhibitors and dietary tyramine: A new experimental model in the conscious rat. J. Pharmacol. Toxicol. Methods 32: 219-224, 1994.
21. FERREY, G., ROVEI, V., STROLIN-BENEDETTI, M., GOMENI, C. AND LANGUILLAT, J.: Antidepressant activity of toloxatone, a selective MAO-A inhibitor, in depressed patients. In Clinical and Pharmacological Studies in Psychiatric Disorders, ed. by C. D. Borrows, T. R. Norman and L. Dennerstein, pp. 83-86, Libbey, Paris, 1985.
22. FITTON, A., FAULDS, D. AND GOA, K. L.: Moclobemide, a review of its pharmacological properties and therapeutic use in depressive illness. Drugs 43: 561-596, 1992.
23. GOLDMAN, L. S., ALEXANDER, R. C. AND LUCHINS, D. J.: Monoamine oxidase inhibitors and tricyclic antidepressants: Comparison of their cardiovascular effects. J. Clin. Psychiatry 47: 5, 1986.
24. HISHIKAWA, Y., NAKAI, K., IDA, H. AND KANEKO, Z.: The effect of imipramine, desmethylimipramine and chlorpromazine on the sleep-wakefulness cycle of the cat. Electroenceph. Clin. Neurophysiol. 19: 518-521, 1965.
25. IRWIN, S.: Comprehensive observational assessment. Ia. A systematic quantitative procedure for assessing the behavioural and physiological states of the mouse. Psychopharmacology (Berlin) 13: 222-257, 1968.
26. JALFRE, M., BUCHER, B., COSTON, A., MOCQUET, G. AND PORSOLT, R. D.: Neuropharmacological profile of MD 780515, a new reversible inhibitor of type A monoamine oxidase. Arch. Int. Pharmacodyn. Ther. 259:194-221, 1982.
27. JARROTT, B. AND VAJDA, F. J. E.: The current status of monoamine oxidase and its inhibitors. Med. J. Aust. 146: 634-638, 1987.
28. JENIKE, M. A., SURMAN, O. S., CASSEM, N. H , ZUSKY, P. AND ANDERSON, W. H.: Monoamine oxidase inhibitors in obsessive compulsive disorder. J. Clin. Psychiatry 44: 131-132, 1983.
29. KOENIG, J. J., MOUREAU, F., VERCAUTEREN, D., DURANT, F., DUCREY, F. AND JARREAU, F. X.: Befloxatone, a spontaneously reversible MAO-A inhibitor: Modelization at molecular level. Clin. Neuropharmacol. 15: 424B, 1992.
30. LECRUBIER, Y. AND GUELFI, J. D.: Efficacy of reversible inhibitors of monoamine oxidase-A in various forms of depression. Acta Psychiatric Scand. 360: 18-23, 1990.
31. LESSIN, A. W.: The pharmacological evaluation of monoamine oxidase inhibitors. Bioch. Pharmacol. 2: 290-298, 1959
32. LITCHFIELD, J T. AND WILCOXON, F.: A simplified method of evaluating dose-effect experiments. J. Pharmacol. Exp. Ther. 96: 99-113, 1949.
33. MACDANIEL, K. D.: Clinical pharmacology of monoamine oxidase inhibitors. Clin. Neuropharmacol. 9: 207-234, 1986.
34. MARLEY, E.: Monoamine oxidase inhibitors and drug interactions. In Drug Interactions. ed. by D. G. Grahame-Smith, pp. 171-177, Macmillan, London, 1977.
35. MARTIN, P., SOUBRIE, PH. AND SIMON, P.: Shuttle-box deficits induced by inescapable shocks in rats: reversal by the beta-adreoceptor stimulants clenbuterol and salbutamol. Pharmacol. Biochem. Behav. 2: 177-181, 1986.
36. MARTIN, P., SOUBRIE, PH. AND SIMON, P.: The effect of monoamine oxidase inhibitors compared with classical tricyclic antidepressants on learned helplessness paradigm. Prog. Neuropsychopharmacol. Biol. Psychiatry 11: 1-7, 1987.
37. MASHKOVSKY, M. D. AND ANDREJEVA, N. I.: Pharmacological properties of 2,3,3a,4,5,6-Hexahydro-8-methyl-1H-pyrazino [3,2,1-j,k]carbazol Hydrochloride (Pirlindole), a new antidepressant. Arzneim-Forsch/Drug Res. 31: 75-79, 1981.
38. MATUZAS, W. AND GLASS, R. M.: Treatment of agoraphobia and panic attacks. Arch Gen. Psychiatry 40: 220-222, 1983.
39. NELSON, S. D., MITCHELL, J. R., TIMBRELL, J. A., SNODGRASS, W. R. AND CORCORAN, G. B.: Isoniazid and iproniazid activation of metabolites to toxic intermediates in man and rat. Science (WAsh. DC) 193: 901-903, 1976.
40. NUTT, D. AND GLUE, P.: Monoamine oxidase inhibitors: Rehabilitation from recent research? Br. J. Psychiatry 154: 287-291, 1989.
41. ORTMANN, R., SCHAUB, M., FELNER, A., LAUBER, J., CHRISTEN, P. AND WALDMEIER, P. C.: Phenethylamine-induced stereotypies in the rat: A behavioural test system for assessment of MAO inhibitors. Psychopharmacology 84: 22-27, 1984.
42. ORTMANN, R., WALDMEIER, P. C., RADEKE, E., FELNER, A. AND DELINI-STULA, A.: The effects of 5-HT uptake and MAO inhibitors on L-5-HTP induced excitation in rats. Naunyn-Schmiedeberg's Arch. Pharmacol. 311: 185-192, 1980.
43. PAYKEL, E. S.: Role of monoamine oxidase inhibitors in the treatment of affective disorders. In Proceedings of the 5th World Congress Biological Psychiatry, Florence, 1991, ed. by Möller and E. S. Paykel, pp. 1-8, Royal Society of Medicine Services, London, 1992.
44. PELLOW, S., CHOPIN, P., FILE, S. E. AND BRILEY, M.: Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Methods 14: 149-167, 1985.
45. POHL, R., BERCHOV, R. AND RAINEY, J. M.: Tricyclic antidepressants and monoamine oxidase inhibitors in the treatment of agoraphobia. J. Clin. Psychopharmacol. 2: 399-407, 1982.
46. PORSOLT, R. D., ANTON, G., BLAVET, N. AND JALFRE, M.: Behavioural despair in rats: A new model sensitive to antidepressant treatments. Eur. J. Pharmacol. 47: 379-391, 1978.
47. PROVOST, J. C., FUNCK-BRENTANO, C., ROVEI, V., D'ESTANQUE, J., EGO, D. AND JAILLON, P.: Pharmacokinetic and pharmacodynamic interaction between toloxatone, a new reversible monoamine oxidase-A inhibitor, and oral tyramine in healthy subjects. Clin. Pharmacol. Ther. 52: 384-393, 1992.
48. RABKIN, J. G., QUITKIN, F. M., HARRISON, W., TRICAM, O. E. AND MCGRATH, P.: Adverse reactions to monoamine oxidase inhibitors. Part I. A comparative study. J. Clin. Psychopharmacol. 4: 270-278, 1984.
49. RABKIN, J. G., QUITKIN, F. M., MCGRATH, P., HARRISON, W. AND TRICAMO, E.: Adverse reactions to monoamine oxidase inhibitors. Part II. Treatment correlates and clinical management. J. Clin. Psychopharmacol. 5: 2-9, 1985.
50. RANDALL, L. O. AND BAGDON, R. E.: Pharmacology of iproniazid and other amine oxidase inhibitors. Ann. N.Y. Acad. Sci. 80: 626-642, 1959.
51. REMICK, R. A., FROESE, C. AND DOUGLAS KELLER, F.: Common side effects associated with monoamine oxidase inhibitors. Prog. Neuropsychopharmacol. Biol. Psychiatry 13: 497-504, 1989.
52. ROVEI, V., CAILLE, D., CURET, O., EGO, D. AND JARREAU, F. X.: Biochemical pharmacology of befloxatone (MD370503), a new potent reversible MAO-A inhibitor. J. Neural. Transm. 41: (Suppl.) 339-347, 1994.
53. ROVEI, V., EGO, D. AND JARREAU, F. X.: Assessment of the interaction between humoryl (toloxatone) and oral tyramine in man. XVIII CINP Kyoto Clin. Neuropharmacol. 1: 43, 1990.
54. SABELLI, H. C., BORISON, R. L., DIAMOND, B. I., HAVDALA, H. S. AND NARASIMHACHARI, N.: Phenylethylamine and brain function. Biochem. Pharmacol. 27: 1729-1730, 1978.
55. 3H-befloxatone. Neuropsychopharmacology 10; 109S, 1994.
56. SCHOERLIN, M. P. AND DA PRADA M.: Species-specific biotrans formation of moclobemide, a comparative study in rats and humans. Acta Psychiatr. Scand. Suppl. 360:108-110, 1990.
57. SHEEHAN, D. V.: Current views on the treatment of panic and phobic disorders. Drug Ther. 7: 74-91, 1982.
58. SHEEHAN, D. V., BALLENGER, J. AND JACOBSON, G.: Relative efficacy of monoamine oxidase inhibitors and tricyclic antidepressants in the treatment of endogenous anxiety. In Anxiety: New Research and Changing Concepts, ed. by D. F. Klein and J. G. Rabkin, pp. 47-62, Raven Press, New York, 1981.
59. TOLLEFSON, G. D.: Monoamine oxidase inhibitors: A review. J. Clin. Psychiatry 44: 280-288, 1983.
60. TYRER, P. AND STEINBERG, D.: Symptomatic treatment of agoraphobia and social phobias: A follow-up study. Br. J. Psychiatry 127: 163-168, 1975.
61. TYRER, P. AND HARRISON-READ, P.: New perspectives in treatment with monoamine oxidase inhibitors. Int. Rev. Psychiatry 2: 331-340, 1990.
62. WILLNER, P.: The validity of animal models of depression. Psychopharmacology 83: 1-16, 1984.
63. WORMS, P., KAN, J. P., WERMUTH, C. G., RONCUCCI, R. AND BIZIERE, K.: SR 95191, a selective inhibitor of type A monoamine oxidase with dopaminergic properties. I. Psychopharmacological profile in rodents. J. Pharmacol. Exp. Ther. 240: 241-249, 1987.
64. WOUTERS, J., MOUREAU, F., VERCAUTEREN, D. P., EVRARD, G., DURANT, F., KOENIG, J. J., DUCREY, F. AND JARREAU, F. X.: Experimental and theoretical study of reversible monoamine oxidase inhibitors: Structural approach of the active site of the enzyme. J. Neural Transm. 41: (Suppl.) 313-319, 1994.
65. ZISOOK, S.: A clinical overview of monoamine oxidase inhibitors. Psychosomatics 2: 241-247, 1985.